Latest Insider Transactions at Adicet Bio, Inc. (ACET)
This section provides a real-time view of insider transactions for Adicet Bio, Inc. (ACET). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adicet Bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adicet Bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 10
2022
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
30,000
-35.96%
|
$600,000
$20.06 P/Share
|
|
Nov 10
2022
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Direct |
9,955
-9.82%
|
$209,055
$21.03 P/Share
|
|
Nov 10
2022
|
Blake Aftab Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,967
-19.81%
|
$146,307
$21.0 P/Share
|
|
Nov 07
2022
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
30,000
-26.45%
|
$570,000
$19.05 P/Share
|
|
Nov 03
2022
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
24,813
-17.95%
|
$446,634
$18.04 P/Share
|
|
Nov 02
2022
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
500
-0.36%
|
$9,000
$18.0 P/Share
|
|
Oct 19
2022
|
Blake Aftab Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,067
-18.66%
|
$129,072
$16.27 P/Share
|
|
Oct 13
2022
|
Blake Aftab Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,933
-15.5%
|
$118,995
$15.92 P/Share
|
|
Oct 12
2022
|
Blake Aftab Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,646
-3.12%
|
$24,690
$15.4 P/Share
|
|
Oct 12
2022
|
Blake Aftab Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,388
+6.03%
|
$23,716
$7.38 P/Share
|
|
Oct 04
2022
|
Chen Schor President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,288
-17.35%
|
$298,032
$14.22 P/Share
|
|
Oct 04
2022
|
Brian Nicholas Harvey Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,096
-10.77%
|
$99,344
$14.22 P/Share
|
|
Oct 04
2022
|
Francesco Galimi SVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,933
-11.27%
|
$111,062
$14.22 P/Share
|
|
Oct 04
2022
|
Don Healey Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,933
-12.51%
|
$111,062
$14.22 P/Share
|
|
Sep 14
2022
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
952
-0.68%
|
$17,136
$18.0 P/Share
|
|
Sep 13
2022
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
3,371
-2.36%
|
$60,678
$18.01 P/Share
|
|
Sep 12
2022
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
66,947
-50.07%
|
$1,138,099
$17.39 P/Share
|
|
Sep 09
2022
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
8,094
-10.81%
|
$129,504
$16.51 P/Share
|
|
Aug 04
2022
|
Chen Schor President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,288
-14.78%
|
$383,184
$18.25 P/Share
|
|
Aug 04
2022
|
Chen Schor President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
48,000
+25.0%
|
-
|
|
Aug 04
2022
|
Francesco Galimi SVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,533
-7.29%
|
$99,594
$18.25 P/Share
|
|
Aug 04
2022
|
Francesco Galimi SVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+17.41%
|
-
|
|
Aug 04
2022
|
Blake Aftab Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,533
-10.07%
|
$99,594
$18.25 P/Share
|
|
Aug 04
2022
|
Blake Aftab Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+22.55%
|
-
|
|
Aug 04
2022
|
Brian Nicholas Harvey Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,696
-6.65%
|
$84,528
$18.25 P/Share
|
|
Aug 04
2022
|
Brian Nicholas Harvey Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+18.47%
|
-
|
|
Aug 04
2022
|
Don Healey Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,533
-8.03%
|
$99,594
$18.25 P/Share
|
|
Aug 04
2022
|
Don Healey Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+18.84%
|
-
|
|
Aug 03
2022
|
Blake Aftab Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,968
-15.17%
|
$125,424
$18.0 P/Share
|
|
Aug 01
2022
|
Blake Aftab Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,968
-13.17%
|
$111,488
$16.64 P/Share
|
|
Jul 06
2022
|
Chen Schor President & CEO |
BUY
Bona fide gift
|
Indirect |
53,424
+27.16%
|
-
|
|
Jul 06
2022
|
Chen Schor President & CEO |
SELL
Bona fide gift
|
Direct |
53,424
-35.75%
|
-
|
|
Jul 05
2022
|
Blake Aftab Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,363
-2.51%
|
$19,082
$14.5 P/Share
|
|
Apr 04
2022
|
Francesco Galimi SVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,979
-4.1%
|
$167,559
$21.0 P/Share
|
|
Apr 04
2022
|
Francesco Galimi SVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,979
+3.82%
|
$95,748
$12.02 P/Share
|
|
Apr 01
2022
|
Francesco Galimi SVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,621
-11.28%
|
$160,041
$21.0 P/Share
|
|
Apr 01
2022
|
Francesco Galimi SVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,621
+10.14%
|
$38,105
$5.97 P/Share
|
|
Mar 09
2022
|
Aya Jakobovits |
SELL
Open market or private sale
|
Indirect |
4,000
-0.56%
|
$56,000
$14.0 P/Share
|
|
Feb 16
2022
|
Aya Jakobovits |
SELL
Open market or private sale
|
Indirect |
4,000
-0.56%
|
$56,000
$14.83 P/Share
|
|
Feb 14
2022
|
Chen Schor President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,288
-12.47%
|
$298,032
$14.27 P/Share
|
|
Feb 14
2022
|
Chen Schor President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
48,000
+21.95%
|
-
|
|
Feb 14
2022
|
Brian Nicholas Harvey Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,696
-7.92%
|
$65,744
$14.27 P/Share
|
|
Feb 14
2022
|
Brian Nicholas Harvey Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+21.25%
|
-
|
|
Feb 14
2022
|
Francesco Galimi SVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,533
-8.45%
|
$77,462
$14.27 P/Share
|
|
Feb 14
2022
|
Francesco Galimi SVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+19.64%
|
-
|
|
Feb 14
2022
|
Blake Aftab Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,533
-9.47%
|
$77,462
$14.27 P/Share
|
|
Feb 14
2022
|
Blake Aftab Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+21.5%
|
-
|
|
Feb 14
2022
|
Don Healey Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,533
-9.46%
|
$77,462
$14.27 P/Share
|
|
Feb 14
2022
|
Don Healey Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+21.49%
|
-
|
|
Feb 09
2022
|
Aya Jakobovits |
SELL
Open market or private sale
|
Indirect |
8,000
-1.1%
|
$112,000
$14.03 P/Share
|